| 05/23 | BAYER : New data support renal and cardiovascular benefits of Kerendia™ (finerenone).. | PU |
| 05/23 | BAYER : Two large Xarelto™ studies support effectiveness of dual pathway inhibition .. | PU |
| 04/29 | BAYER : “Bayer is on the right track” | PU |
| 04/22 | BAYER : submits application in China for additional indication of darolutamide | PU |
| 04/13 | BAYER : receives approval for precision oncology treatment Vitrakvi™ in China | PU |
| 04/07 | Chinese man sentenced for stealing Monsanto trade secret | AQ |
| 04/06 | BAYER : Early redemption / Cancellation / Delisting | PU |
| 04/04 | BAYER : New data for finerenone on the risk reduction of cardiovascular and renal outcomes.. | PU |
| 04/04 | BAYER : XARENO study revealed Xarelto™ was associated with net clinical benefit and .. | PU |
| 04/04 | BAYER : honors three young agricultural leaders with an award supporting the projects they.. | PU |
| 04/03 | BAYER : presents positive results from first Phase 2b trial on safety of asundexian in pat.. | PU |
| 04/01 | BAYER : set to drive breakthrough innovations in the Life Sciences | PU |
| 03/31 | BAYER : to strengthen global Pharmaceuticals production network | PU |
| 03/29 | Bayer receives approval in Japan for Kerendia (finerenone), a new treatment for adults .. | AQ |
| 03/29 | BAYER : to present data from cardiovascular portfolio including late-breaking presentation.. | PU |
| 03/28 | BAYER : receives approval in Japan for Kerendia™ (finerenone), a new treatment for a.. | PU |
| 03/22 | BAYER : refinances 1.3 billion euro hybrid bond | PU |
| 03/22 | Evotec receives EUR 3 m milestone payment for Bayer starting Phase II clinical developm.. | AQ |
| 03/16 | BAYER : 2021 Hansen Family Award goes to Professor Kai Johnsson | PU |
| 03/16 | BAYER : submits application in the EU for an extension of the indication of finerenone to .. | PU |
| 03/11 | BAYER : submits application for additional indication of Nubeqa™ (darolutamide) in J.. | PU |
| 03/09 | BAYER : submits applications in the U.S. and EU for additional indication of Nubeqa™.. | PU |
| 03/02 | BAYER : Rezultate financiare 2021 - transmis de SSIF TRADEVILLE SA | PU |
| 03/01 | BAYER : Annual Report 2021 German (PDF, 3.09 MB) | PU |
| 02/24 | BAYER : extends clinical development program for finerenone with Phase II study investigat.. | PU |
| 02/21 | BAYER : delivers on medical innovation fueling transformation of pharma business | PU |
| 02/21 | BAYER : new treatment Kerendia® (finerenone) approved in EU for adult patients with chroni.. | PU |
| 02/16 | BAYER : highlights advancements of agriculture industry's most prolific R&D pipeline | PU |
| 02/10 | BAYER : Receives U.S. FDA Fast Track Designation for asundexian Stroke Program | PU |
| 02/09 | Bayer - AskBio and Touchlight Restructure Joint Venture | AQ |
| 02/04 | BAYER : will discontinue phase II development candidate eliapixant | PU |
| 01/19 | BlueRock Therapeutics Announces First Patient Dosed in Canada in Phase 1 Trial in Patie.. | AQ |
| 01/17 | BAYER : Annual Bayer Pharma Media Day 2022 | PU |
| 01/07 | Ex-Monsanto employee pleads guilty to corporate spying for China | AQ |
| 01/07 | AVOIDING A TOXIC SITUATION : Lessons From Bard V. Monsanto | AQ |
| 01/06 | Chinese man pleads guilty to stealing Monsanto trade secret | AQ |
| 01/06 | Monsanto pleads guilty to pesticide-related crimes in Hawaii | AQ |
| 01/03 | Hansa Biopharma enters into agreement with AskBio to evaluate feasibility of imlifidase.. | AQ |
| 2021 | Interim Report 2 (2021-08-01 - 2021-10-31) | AQ |
| 2021 | BAYER : U.S. FDA approves Xarelto™ to treat venous thromboembolism (VTE) and to prev.. | PU |
| 2021 | BAYER : receives positive CHMP opinion for finerenone as a new treatment for adult patient.. | PU |
| 2021 | BAYER : Phase III trial with Nubeqa™ (darolutamide) in combination with docetaxel an.. | PU |
| 2021 | BAYER : Phase III trial with darolutamide in combination with docetaxel and androgen depri.. | PU |
| 2021 | Couple's $86M reward in Monsanto pesticide case stands | AQ |
| 2021 | BAYER : extends clinical development program for finerenone with Phase III study in childr.. | PU |
| 2021 | New Phase III study to investigate expanded use of vericiguat in patients with chronic .. | PU |
| 2021 | Bayer Submits Aflibercept for regulatory approval in the EU and Japan for Retinopathy o.. | PU |
| 2021 | Rodrigo Santos named member of the Board of Management, Bayer AG, and President of the .. | PU |
| 2021 | Bayer grows sales and earnings significantly | PU |
| 2021 | New data from finerenone clinical trial program reinforces renal and cardiovascular ben.. | PU |
| 2021 | Bayer to present data from cardiovascular portfolio, including analyses from the compre.. | PU |
| 2021 | European Patent Office maintained Bayer patent on the once-daily administration of riva.. | PU |
| 2021 | Bayer to present new data from comprehensive finerenone clinical trial program | PU |
| 2021 | BAYER : Belmora Seeks SCOTUS Review For The Second Time In Its Cross-Border Trademark Batt.. | AQ |
| 2021 | BAYER : Gadovist™ (Gadobutrol) at a Reduced Dose Demonstrates Non-Inferiority Compar.. | PU |
| 2021 | BAYER : New data for rivaroxaban in patients following the Fontan procedure and at risk fo.. | PU |
| 2021 | BAYER : Middle East announces partnership with the United Nations Population Fund Egypt, t.. | PU |
| 2021 | BAYER : extends clinical development program for finerenone with Phase III study in patien.. | PU |
| 2021 | BAYER : launches transparency register for scientific collaborations with external partner.. | PU |
| 2021 | BAYER : Latest analyses of Vitrakvi (larotrectinib) reaffirm powerful efficacy and tolerab.. | PU |
| 2021 | BAYER : Andes Raises USD 15 Million in Series A Funding Co-Led by Leaps by Bayer and Caval.. | BU |
| 2021 | BAYER : to highlight expanded research from growing oncology portfolio at ESMO Congress 20.. | PU |
| 2021 | BAYER : Eliapixant significantly decreased cough frequency in Phase IIb trial in patients .. | PU |
| 2021 | BAYER : starts Phase III clinical development program OASIS with Elinzanetant | PU |
| 2021 | BAYER : New Data on Finerenone for the protection of patients with chronic kidney disease .. | AQ |
| 2021 | BAYER : New Data on Finerenone for the protection of patients with chronic kidney disease .. | PU |
| 2021 | BAYER : U.S. FDA approves expansion of the peripheral artery disease (PAD) indication for .. | PU |
| 2021 | BAYER : to present data from cardiovascular portfolio, including late breaking data from P.. | PU |
| 2021 | BAYER : to present data from cardiovascular portfolio, including late breaking data from P.. | PU |
| 2021 | BAYER : Belmora Files Petition For Writ Of Cetiorari In Long-Running FLANAX Battle With Ba.. | AQ |
| 2021 | BAYER : strengthens-drug-discovery-platform-through-acquisition-of-Vividion-Therapeutics | AQ |
| 2021 | BAYER : Half-Year Financial Report 2021 English (PDF, 582 KB) | PU |
| 2021 | BAYER : Strong growth, guidance upgrade | PU |
| 2021 | BAYER : strengthens drug discovery platform through acquisition of Vividion Therapeutics | PU |
| 2021 | BAYER : investigational P2X3 antagonist meets primary efficacy endpoint and shows favorabl.. | AQ |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
